IE48602B1 - Pharmaceutical composition for rectal administration of 7-(d(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazinylcarboxamide)-p-hydroxyphenyl acetamido)-3-(5-(1-methyl-1,2,3,4-tetrazolyl)thiomethyl)-delta3-cephem-4-carboxylic acid or salts - Google Patents
Pharmaceutical composition for rectal administration of 7-(d(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazinylcarboxamide)-p-hydroxyphenyl acetamido)-3-(5-(1-methyl-1,2,3,4-tetrazolyl)thiomethyl)-delta3-cephem-4-carboxylic acid or saltsInfo
- Publication number
- IE48602B1 IE48602B1 IE1411/79A IE141179A IE48602B1 IE 48602 B1 IE48602 B1 IE 48602B1 IE 1411/79 A IE1411/79 A IE 1411/79A IE 141179 A IE141179 A IE 141179A IE 48602 B1 IE48602 B1 IE 48602B1
- Authority
- IE
- Ireland
- Prior art keywords
- pharmaceutical composition
- salt
- oil
- acid
- rectal administration
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 title claims abstract description 15
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 20
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims abstract description 13
- 239000003613 bile acid Substances 0.000 claims abstract description 13
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 12
- 239000002585 base Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 21
- -1 aliphatic alcohols Chemical class 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 235000019483 Peanut oil Nutrition 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 8
- 235000019198 oils Nutrition 0.000 claims description 8
- 239000000312 peanut oil Substances 0.000 claims description 8
- 235000005687 corn oil Nutrition 0.000 claims description 6
- 239000002285 corn oil Substances 0.000 claims description 6
- 239000003925 fat Substances 0.000 claims description 6
- 235000019197 fats Nutrition 0.000 claims description 6
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 5
- 235000014121 butter Nutrition 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021314 Palmitic acid Nutrition 0.000 claims description 2
- 239000004264 Petrolatum Substances 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 2
- 244000299461 Theobroma cacao Species 0.000 claims description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 claims description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
- 150000001346 alkyl aryl ethers Chemical class 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- 150000008051 alkyl sulfates Chemical group 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 229940092738 beeswax Drugs 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 claims description 2
- 235000001046 cacaotero Nutrition 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229960000541 cetyl alcohol Drugs 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 239000002385 cottonseed oil Substances 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- 229940031578 diisopropyl adipate Drugs 0.000 claims description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- 239000012182 japan wax Substances 0.000 claims description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 235000021313 oleic acid Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- 229940066842 petrolatum Drugs 0.000 claims description 2
- 239000010491 poppyseed oil Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 claims description 2
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 2
- 239000008159 sesame oil Substances 0.000 claims description 2
- 235000011803 sesame oil Nutrition 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 229940023144 sodium glycolate Drugs 0.000 claims description 2
- 239000012177 spermaceti Substances 0.000 claims description 2
- 229940084106 spermaceti Drugs 0.000 claims description 2
- 229940031439 squalene Drugs 0.000 claims description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 239000003760 tallow Substances 0.000 claims description 2
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 210000002268 wool Anatomy 0.000 claims description 2
- YGBFLZPYDUKSPT-MRVPVSSYSA-N cephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C[C@H]21 YGBFLZPYDUKSPT-MRVPVSSYSA-N 0.000 claims 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 241001553178 Arachis glabrata Species 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 239000002199 base oil Substances 0.000 claims 1
- 235000015278 beef Nutrition 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- 229940012831 stearyl alcohol Drugs 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 229940126062 Compound A Drugs 0.000 description 25
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 25
- 239000006185 dispersion Substances 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 14
- 239000000829 suppository Substances 0.000 description 14
- 159000000000 sodium salts Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229930186147 Cephalosporin Natural products 0.000 description 6
- 229940124587 cephalosporin Drugs 0.000 description 6
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 5
- 150000001780 cephalosporins Chemical class 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940055577 oleyl alcohol Drugs 0.000 description 5
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 5
- 239000007901 soft capsule Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000001271 cephalosporin group Chemical group 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000004826 seaming Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A pharmaceutical composition for rectal administration comprises 7-[D(-)- alpha -(4-ethyl-2,3-dioxo-1- piperazinylcarboxamido)-p- hydroxyphenylacetamido]-3-[5-(1- methyl-1,2,3,4-tetrazolyl)thiomethyl]- DELTA <3>-cephem-4-carboxylic acid or its pharmaceutically acceptable salt, an oily base, and a nonionic surfactant and/or an anionic surfactant and/or a salt of bile acid and is well absorbed in a living body and maintained in a high concentration in blood for a long period of time.
Description
This invention relates to a pharmaceutical composition of cephalosporin for rectal administration.
The term cephalosporin used herein means 7-(0(-)- a -(4-ethyl-2,3-dioxo-1-piperazinylcarboxamido)5 p-hydroxyphenylacetamido]-3-[5-(l-methyl-l,2,3,4-tetrazolylJthiomethylj-A^-cephem-Vearboxylic acid represented by the following structural formula and a pharmaceutically acceptable salt thereof which have been developed by Saikawa et al., Saikawa being one of the present inventors (see British Patents 1,508,071 and The compound represented by said structural formula is hereinafter referred to as Compound A. Compound A has a broad antibacterial spectrum against gram-positive and gram-negative bacteria and particularly exhibits an effective antibacterial activity against Pseudomonas aeruginosa, Klebsiella pneumoniae and Proteus species which have been known as causes for clinically serious infectious diseases, and are very stable against β-lactamase produced from bacteria. Thus, Compound A is a very useful therapeutic drug for human infectious diseases.
When Compound A is injected in the form of a 5 pharmaceutically acceptable salt (as intravenous injection, intramuscular injection or drip infusion), it is well absorbed in a living body. However, injections are difficult to use at home and the pain due to injection inspires infants with fear. This is disadvantageous.
On the other hand, oral administration or rectal administration (suppository) are advantageous in that the drug can be used relatively simply without inspiring patients with fear. However, when Compound A or its pharmaceutically acceptable salt is administered orally, it is little absorbed in a living body, and therefore, a high concentration in blood cannot be achieved. Further, the present inventors have found that when Compound A or its pharmaceutically acceptable salt is dispersed in an oily base or a water-soluble base according to the conventionally known method for preparing a pharmaceutical preparation for rectal administration and the preparation thus obtained is administered by rectal route, the compound Is little absorbed in a living body and no effect is obtained.
The present inventors, therefore, have conducted extensive research on pharmaceutical compositions to be administered by rectal route which can be well absorbed in a living body and can be maintained in - 3 48602 a high concentration in blood for a long period of time, and as a result, have found that when a uniform dispersion of Compound A or its pharmaceutically acceptable salt in a mixture of an oily base and a nonionic surfactant and/or an anionic surfactant and/or a salt of bile acid is administered by rectal route, Compound A is well absorbed in a living body to obtain a high concentration in blood.
An object of this invention is to provide a 10 pharmaceutical composition of a cephalosporin, for rectal administration.
A further object of this invention is to provide a pharmaceutical composition of a cephalosporin which can be well absorbed in a living body and can be maintained in a high concentration in blood for a long period of time when administered by rectal route.
Other objects and advantages of this invention will be apparent from the following description.
According to this invention, there is provided 20 a pharmaceutical composition of 7-[D(-)-a-(4-ethyl-2,3dioxo-l-piperazinylcarboxamido)-p-hydroxyphenylacetamido 3—3—C 5—(1-methyl-l,2,3 >4-tetrazolyl)thiomethylj-A^cephem-4-carboxylic acid or its pharmaceutically acceptable salt which comprises 7-[D(-)-a-(4-ethyl-2,325 dioxo-l-piperazinylcarboxamido)-p-hydroxyphenylacetamido]-3-E5-(1-methyl-l,2,3,4-tetrazolyl)thiomethyl]A3-cephem-4-carboxylic acid or its pharmaceutically acceptable salt, an oily base, and a nonionic surfactant - 4 48602 and/or an anionic surfactant and/or a salt of bile acid.
According to this invention, when a pharmaceutically acceptable salt of Compound A is used, a particularly high concentration in blood can be obtained. As such pharmaceutically acceptable salts of Compound A, there may be exemplified salts with alkali metals such as sodium, potassium and the like; salts with alkaline earth metals such as calcium, magnesium and the like; ammonium salts; salts with organic bases such as procain, dibenzylamine, N-benzyl-6-phenethylamine, 1-ephenamine, arginine, trishydroxymethylaminomethane and the like.
As the nonionic surfactant used in this invention, there may be exemplified polyoxyethylene fatty alcohol ethers of the polyethylene glycol type (for example, Emulgen 120, Emulgen 220, Emulgen ^08 and Emulgen 420, trade names of Kao Sekken, and Nikkol BC-15TX, Nikkol BC-20TX and Nikkol BO-2Q, trade names of Nikko Chemicals); polyoxyethylene alkylaryl ethers (for example, Emulgen 920, trade name of Kao Sekken and Nikkol NP-7.5, trade name of Nikko Chemicals); polyoxypropylenepolyoxyethylene alkyl ethers (for example, Pluronic Lfi2, trade name of Asahi Denka); sugar esters of fatty acid esters type (for example, DK Ester F-140, trade name of Dai-ichi Kogyo Seiyaku) and the like.
In general, the nonionic surfactants of the polyethylene glycol type having an HLB of 10 to 14 are preferred to those of the polyhydric alcohol type.
As the anionic surfactant, there may be - 5 48602 exemplified, alkyl sulfates (for example, Emerl 10 powder, trade name of Kao Sekken); di-alkyl sulfosuccinates (for example, Rapizole B-90, trade name of Nippon Oil & Fats Co., Ltd.), and as the salt of bile acid, there may be exemplified sodium tauroglycolate, sodium glycolate, sodium taurocholate and. the like.
In this invention, at least two of the surfactants mentioned above may be used in admixture.
The total amount of the nonionic surfactant, the anionic surfactant and the salt of bile acid used in this invention may be 1 to 20$ by weight based on the weight of the oily base, and an amount of 5 to 10$ by weight is particularly preferable.
As the oily base used in this invention, there 15 may be examplified bases having themselves no pharmaceutical activity as used in the production of conventional ointments, suppositories and the like, for example, fats and oils such as peanut oil, sesame oil, soybean oil, corn oil, rape seed oil, cotton seed oil, caster oil, tubaki oil, coconut oil, olive oil, poppy seed oil, cacao butter, laurin butter, beaf tallow, squalene, wool fat and'the like; those fats and oils that have been modified by chemical reaction, such as hydrogeneration (petrolatum) or the like; mineral oils such as vaselin,/paraffin, silicone oil and the like; higher fatty acid esters such as isopropyl myristate, n-butyl myristate, isopropyl linolate, cetyl ricinolate, stearyl ricinolate, diethyl sebacate, diisopropyl adipate, and the like; higher - 6 48602 aliphatic alcohols such as cetyl alcohol, stearyl alcohol and the like; waxes such as bleached bees wax, spermaceti, Japan wax and the like; higher fatty acids such as stearic acid, oleic acid, palmitic acid and the like; and mixtures of triglycerides of naturally occurring saturated fatty acids having 12 to 18 carbon atoms in which the whole of the hydroxyl groups have been esterified and triglycerides of said fatty acids In which a part of the hydroxyl groups has been esterified. Vegetable oils are particularly preferable.
These oily bases may be used alone or in admixture of two or more. The amount of the oily base used is 1 to 20 times the weight of Compound A or its pharmaceutically acceptable salt used, and an amount of 2 to 18 times is preferred.
In the preparation of the composition of this invention, the nonionic surfactant and/or the anionic surfactant and/or the salt of bile acid is first dispersed in the oily base, and the necessary amount of Compound A or its pharmaceutically acceptable salt is added to the resulting dispersion and uniformly dispersed in the latter. However, in this invention, the order of adding the base, the surfactants and the cephalosporin is not limited to the above-mentioned one. The particle size of Compound A and its pharmaceutically acceptable salt is preferably 100 μ or less.
In preparing a pharmaceutical preparation from the composition thus obtained, the composition may be - 7 48602 formed into a conventional anal suppository, or a suspension or an ointment in which the surfactant and the cephalosporin are dispersed in the .oily base may be put in a soft capsule, or said dispersion or ointment may be put in a tube, which is infused at the time of use.
To the above preparations may be added antioxidants such as tocopherol, BHA, NDSA and the like; synergists such as phosphoric acid, citric acid, ascorbic acid, malonic acid; antiseptics; concealing agents; excipients; and the like.
The effective administration amount of the composition of this invention may be varied depending upon Compound A or its pharmaceutically acceptable salt, and such an amount of the composition may be selected that said compound may be administered in an amount 1/5 to 3 times the effective administration amount in the case of an injection.
This invention is illustrated below with reference to Examples, which are merely by way of illustration and not by way of limitation.
Application Example A dispersion of Compound A or its sodium salt in a mixture of an oily base, and various surfactants and/or a salt of bile acid (the present invention); a dispersion of the sodium salt of Compound A in physiological saline solution as an injection (control); a dispersion of the sodium salt of Compound A in water - 8 48602 (control); a dispersion of the sodium salt of Compound A in an oily base (peanut oil) only (control); and a dispersion of the sodium salt of Compound A in a watersoluble base (propylene glycol) only (control) were administered rectally, orally or by injection, and changes of concentration in blood with the lapse of time were compared.
The method of administration of a sample was as follows: In the case of rectal administration, each sample was administered through anus into the rectum of a male Wister rat (weight: about 350 g), which had been abstained from food for 15 hours, by using a small injector or by Inserting a Witepsol suppository obtained by pouring the sample into a mold for suppository and solidifying the same therein. After the administration, the anus was sewed up with surgical seaming thread Nos. to 6.
In the case of oral administration, each sample was administered to the above rats by means of a sonde for rat.
The measurement of concentration in blood was conducted as follows: The neck of a rat was operated at a certain interval of time and a small amount of blood was sampled from the jugular vein, and the concentration of the compound therein was quantitatively determined by a conventional bioassay method. Bacillus subtills ATCC 6633 was used as an examination bacterium and the - 9 48602 culture medium was prepared by adding water to a mixture of 5 g of peptone, 3 g of meat extract and 15 g of agar in such an amount that the total volume became one liter, and adjusting the pH thereof to 6.2. The volume of the seed layer was 8 ml.
In measuring a concentration as low as 2 pg/ml or less, Micrococcus luteus ATCC 93^1 was used as the examination bacterium, and the culture medium was prepared by adding water to a mixture of 10 g of peptone, 2.5 g of sodium chloride, 5 g of meat extract and 15 g of agar in such an amount that the total volume became one liter and adjusting the pH thereof to 6.5· The volume of the seed layer was 8 ml.
The serum was separated from the sampled blood by centrifugation at 3000 r.p.m. and cultivated at 37°C for a period of 16 to 20 hours by the paper disc method and then examined. A 1% phosphate buffer solution (pH: 6.0) was used as the solution for calibration curve. The results obtained are shown in Table 1.
(Amount of Compound. A or its sodium salt administered was 100 mg/kg) Concentration in blood (mcg/ml) o C «Η CM £ <0.1 0.2 <0.1 <0.1 <0.1 η -) 120 min <0.1 0.2 1 <0.1 : <0.1 <0.1 C c Ο Ή VO £ <0.1 0.2 0.2 <0.1 <0.1 30 min <0.1 0.2 1 m o <0.1 <0.1 c H £ <0.1 I 0.2 0.8 <0.1 0.2 Sample composition Surfactant or salt of bile acid 40 1 I1 I I Name i 1 1 1 1 Compound A or its sodium salt and base Sodium salt of ! Compound A 5% Water 95% Sodium salt of Compound A 5% Peanut oil 95% I Compound A 5% Peanut oil 95% Compound A 5% Water 95% Sodium salt of Compound A 5% Water 95% Admini- stra- tion method Rectally -1 Rectally «Ή rd d •P O Θ λ Orally Orally 1 Con- trol Cont'd I ΙΑ ο rσ <η ο CM CM la rd VO rd O CO Cont 'd cn LA o o rd cn co vo CM co CM rd o rd cn o co la rd -Ρ £ Ο Ο ι—i rd Χ3 cd Ε-< X! Eh rd O O Λ2 CM rf I •Η O 2 rf £ faOco rd O £ -T ε ω x E-* rd O o rf CM rf I Td O rf £ tO co rd O £ -=r ε td £ rd 0) £ TJ 0 £ S 0 td a x Ed rd O o rf cm rf I Td o 2 m O rd £ CD bOco rd O ε^ Pd rd LA O · rfcrf Td rf 22 O LA rd CO o rd < rd vd XJ o £ £ -P 0 2 a £ ε d ο 0 o cu X5 rd C -H £ O O a £ ε £ o o •o o XJ rd C O LA £ CQ rd o a i a 0 rf ε -p O -H o Ό rd £ Ο IA £ CQ rd o a I a 0 a ε -p O *rd o 2 4-1 CAO ο σ\ -P rd O £ a £ ε Td XJ O CQ O Pm ¢-/ LA O O O\ -P rd *£ rd Cd *H cq£ O £ ε £ -p £ O £ ♦h a £ ε cd Ο O 0 CQ O rf rf Ο O O rdCO -P rd < cd CQ XJ rd £ Ή ε £ o £ O Td a £ xj ε & o o o CQ Ο O rf Ο O O rd00 -P rd rd «£ ·Η cd O CQ <£ £ cd O 0 ao ε >5 o o O 02 rd rd cd -P cd -P ϋ 0) rf cd -P ο rf cd •P rf cd •p o rf rd cd -P o rf rd rd cd -P o rf >> rd rd cd p o rf -P c CQ £ Pm I £ > £ £ O Td -p Table 1 (Cont'd) r-4 o V j=r ο -=r i£> <0.1 <0.1 0.3 CM σ\ o cn H b- ο 4Γ O © O r—1 V CM m o in t— Ch CM CM m I—i © H rH cn © cn o =r cn M3 t— co o m -=T CM cn tn -=Γ o o -=r m CM co CM M3 m CM H H f—J o O o Lf\ in © i-1 rH r—{ Γ—i d X O c Φ 3 (U H 4) & S 1 43 H a hO CO ω o tflco 3 O tti 0 o o r—t O id -=r H O H d H 3d CM d CM 3 -=3* 3 -=r Ό 3 O 44 1 3 M3 e id 1 E o to a Η O Η 1 Ed Q Ed Ed CO 4-3 O Z CQ Ph J ¢-1 5-4 ΊΛ W. 0 oo cp o o C-i o o dino mo O © o cm r~ o HCO 0 cm ¢- o cn 43 O\ +3 i—ICO r-J 4_> 4-3 CM 43 Η cd cd H i—1 <4 H H < H W < H to < —1 ΰί H id co cd Cd H H o ΜΌ Ο to tj OT Ό H M3 0 ¢) Ό 0 aj Ό c c H C O P 3 C CSC £ 3 -Ρ 6 3 0 E 3 in Lt\ E 3 4J H 3 4? •H 3 tt) 3 0 3 3 O fb 3 O C4H 3 0 3 C 0 3 COO Η Λ Φ 1 •H Q. C •h ac H &42 Xj £ rtJ τ) ε ω Ό E -PS3 3 S d hO κ cd 60 E >> Ο Ο Φ OOH OOH 0 Ο d 0 <1> d Ο O go ο ο- ΛϋΕ Μ O 3 CO O id •a: o cu >, >3 >» >5 >i >3 r-i H i—1 H i-4 r-4 H CTJ cd cd cd cd cd •Ρ -P 4J 43 43 43 ο o O O O O 4> CD o 0) Λ EH cd ch CH CH 4-3 C 1 o c n 4> G 0 > 0 d q h Ed Η Η As is clear from Table 1, when the sample of this invention was rectally administered, a much higher concentration in blood was obtained than when the control samples were administered orally or rectally.
Production Example 1 In 85 g of corn oil was dispersed 5 g of a nonionic surfactant polyoxyethylene oleyl alcohol ether (Emulgen 408) and thereafter 10 g of 7-[D(-)-a-(4-ethyl2,3-dioxo-l-piperazinylearboxamido)-p-hydroxyphenyl10 acetamido]-3-[5-(l-methyl-l,2,3,4-tetrazolyl)thiomethyl]•3 Δ -cephem-4-carboxylic acid was added to the dispersion, after which the resulting mixture was stirred to disperse the carboxylic acid uniformly in the dispersion. A gelatine soft capsule was filled with the resulting dispersion in an amount of 1.25 g per capsule to prepare a soft capsule suppository.
Production Example 2 On a water bath at 380 to 45°C, 80 g of a triglyceride of a higher fatty acid (Witepsol H-15j trade name of'Dynamite Nobel) was melted, and thereto was dissolved 10 g of a nonionic surfactant polyoxyethylene oleyl alcohol ether (Nikkol BC - 20 TX), after which 10 g of 7-CD(-)-a-(4-ethyl-2,3-dioxo-l-piperazinylcarboxamido)-p-hydroxyphenylacetamido]-3-C5-(1-methyl25 l,2,3,4-tetrazolyl)thiomethyl]-A^-cephem-4-carboxylic acid was added to the resulting solution. The resulting - 14 48602 mixture was stirred to form a uniform dispersion, which was then cooled to a temperature near the freezing point and thereafter poured into a mould for rectal suppository to prepare a solid suppository.
Production Example 3 To 80 g of soybean oil was added 10 g of a nonionic surfactant polyoxyethylene nonylphenyl ether (Nikkol NP 7.5), and the latter was dispersed in the former, after which 10 g of sodium 7-[D(-)-a-(4-ethyl10 2,3-dioxo-l-piperazinylcarboxamido)-p-hydroxyphenyacetamido]-3-L5-(l-methyl-l,2,3,4-tetrazolyl)thiomethyl]-A^cephem-4-carboxylate was added to the resulting dispersion. The resulting mixture was then stirred to form a uniform dispersion. In the same manner as in Production Example 1, a soft capsule suppository was prepared.
Production Example 4 To 80 g of corn oil were added 10 g of a nonionic surfactant (Emulgen 408) and then 10 g of sodium 7-[D(-)-a-(4-ethyl-2,3-dioxo-l-piperazinylcarbox20 amido)-p-hydroxyphenylacetamido]-3-(5-(1-methyl-1,2,3,4tetrazolyl)thiomethyl]-A^-cephem-4-carboxylate, and the resulting mixture was stirred to form a uniform dispersion. In the same manner as In Production Example 1, a soft capsule suppository was subsequently prepared. - 15 48602 Production Example 5 To 80 g of corn oil were added 10 g of a nonionic surfactant (Emulgen 408) and then 10 g of sodium 7-[D(-)-a-(4-ethyl-2,3-dioxo-l-piperazinylcarbox5 amido)-p-hydroxyphenylacetamido]-3-C5-(1-methyl-l,2,3,4tetrazolyl)thiomethyl]-h -cephem-4-carboxylate, and the resulting mixture was stirred to form a uniform dispersion. This dispersion was put in a suppository tube.
Production Example 6 To 9θ g of peanut oil were added 5 g of an anionic surfactant sodium laurylsulfate (Emerl 10 powder), and then 10 g of sodium 7-[D(-)-a-(4-ethyl2,3-dioxo-1-pi peraz inylc arboxamido)-p-hydroxyphenyl acetamido]-3-[5-(1-methyl-1,2,3,4-tetrazolyl)thiomethyl] Δ -cephem-4-carboxylate, and the resulting mixture was stirred to form a uniform dispersion, which was then put in a suppository tube.
Production Example 7 On a water bath at 38° to 45°C, 70 g of a triglyceride of a higher saturated fatty acid (Witepsol H - 15) was melted, and therein was dissolved 10 g of a nonionic surfactant polyoxyethylene oleyl alcohol ether (Emulgen 408). To the resulting solution was added 20 g of sodium 7-[D(-)-a-(4-ethyl-2,3-dioxo-l-pipera25 zinylcarboxamido)-p-hydroxyphenylacetamido]-3-C5-(lmethyl-1,2,3,4-tetrazolyl)thiomethyl]-A^-cephem-4- 16 48602 carboxylate, and the resulting mixture was stirred to form a uniform dispersion. In the same manner as in Production Example 2, a solid suppository was prepared.
Production Example 8 In 80 g of peanut oil were dispersed 8 g of polyoxyethylene oleyl alcohol ether (Emulgen 408) and 2 g of sodium taurocholate, after which 10 g of sodium 7-ED(-)-a-(4-ethyl-2,3-dioxo-1-piperazinylcarboxamido)p-hydroxyphenylacetamidoJ-3-[5-(1-methyl-l,2,3, 4-tetra10 zolyDthiomethyll-A^-cephem-it-carboxylate, and the resulting mixture was stirred to form a uniform dispertion. A suppository tube was filled with this dispersion.
Production Example 9 On a water bath at 38° to 45°C, 80 g of a triglyceride of a higher saturated fatty acid (Witepsol H-15) was melted, and therein were dissolved 7 g of a nonionic surfactant polyoxyethylene oleyl alcohol ether (NIkkol BC - 20 TX) and 3 g of sodium laury sulfate'(Emerl 10 powder). To the resulting solution was added 10 g of sodium 7-ED(-)-a-(4-ethyl-2,3-dioxol-piperazinylcarboxamido)-p-hydroxyphenylacetamido]~3~ E5-(1-methyl-l,2,3,4-tetrazolyl)thiomethyl]-A3-cephem4-carboxylate, and the resulting mixture was stirred to form a uniform dispersion. In the same manner as in Production Example 2, a solid suppository was prepared. The words Pluronic Vaseline and Witepsol used herein are Trade Marks.
Claims (18)
1. A pharmaceutical composition for rectal administration which comprises 7-[D(-)-a-(4-ethyl-2,3dioxo-l-piperazinylcarboxamido)-p-hydroxyphenylaeetamido]^ S 3-(5-(1-met hyl-1,2,3,4-tetrazolyl)thiomethyl]-Δ^cephem-4-carboxylic acid or its pharmaceutically acceptable salt, an oily base, and a nonionic surfactant and/or an anionic surfactant and/or a salt of bile acid.
2. A pharmaceutical composition for rectal >0 administration according to Claim 1, which consists essentially of 7-(D(-)-a-(4-ethyl-2,3-dioxo-lpiperazinylcarboxamido)-p-hydroxyphenylaeetamido]-3(5-(1-met hyl-1,2,3,4-tetrazolyl) thiomethyl]-Δ 3 -cephem4-carboxyllc acid or its pharmaceutically acceptable salt, an oily base and a nonionic surfactant.
3. A pharmaceutical composition for rectal administration according to Claim 1, which consists essentially of 7-(D(-)-a-4-ethyl-2,3-dioxo-lpi peraz inylc arb oxamido)-p-hydroxyphenylacetamido]-3(5-(1-methyl-1,2,3,4-tetrazolyl)thiomethyl j-A^-cephem4-carboxylic acid or its pharmaceutically acceptable salt, ah oily base and an anionic surfactant.
4. A pharmaceutical composition for rectal administration according to Claim 1, which consists 2j5 essentially of 7-(D(-)-a-(4-ethyl-2,3-dioxo-lpiperazinylcarboxamido)-p-hydroxyphenylacetamido]-3(5-(1-methyl-1,2,3,4-tetrazolyl)thiomethyl]-A -cephem4-carboxylic acid or its pharmaceutically acceptable - 18 48602 salt, an oily base and a salt of bile acid.
5. A pharmaceutical composition for rectal administration according to any one of Claims 1 to 4, wherein the oily base is at least one member selected 5 from the group consisting of fats and oils; hydrogenated fats and oils; mineral oils; higher aliphatic alcohols; higher fatty acid esters; higher fatty acids; waxes; and triglycerides of naturally occuring saturated fatty acids having 12 to 18 carbon atoms. 10
6. A pharmaceutical composition for rectal administration according to any one of Claims 1 to 4, wherein the oily base is at least one vegetable oil.
7. A pharmaceutical composition for rectal administration according to Claim 5, wherein the oily (5 base is at least one member selected from the group consisting of peanut oil, sesame oil, soybean oil, corn oil, rape seed oil, cotton seed oil, castor oil, tubaki oil, coconut oil, olive oil, poppy seed oil, cacao butter, laurin butter, beef tallow, squalene, AO wool fat,petrolatum, paraffin, silicone oil, Isopropyl myristate, n-butyl myristate, isopropyl linolate, cetyl ricinolate, stearyl ricinolate, diethyl sebacate, diisopropyl adipate, cetyl alcohol, stearyl alcohol, bleached bees wax, spermaceti, Japan wax, stearic acid, oleic acid, palmitic acid and a mixture of a triglyceride of a naturally occurring higher saturated fatty acid having 12 to 18 carbon atoms in which the whole of the hydroxyl groups have - 19 48602 been esterified and a triglyceride of a naturally occurring higher saturated fatty acid having 12 to 18 carbon atoms in which a part of the hydroxyl groups have been esterified. ‘S
8. A pharmaceutical composition for rectal administration according to Claim 5, wherein the base oil is peanut oil, corn oil, a triglyceride of a higher fatty acid, or soybean oil.
9. A pharmaceutical composition for rectal
10. Administration according to Claim 1 or 2, wherein the nonionic surfactant is a polyoxyethylene higher alcohol ether, a polyoxyethylene alkylaryl ether, a polyoxypropylene-polyoxyethylene alkyl ether or a fatty acid ester of sucrose. '5 io, A pharmaceutical composition for rectal administration according to Claim 1 or 2, wherein the nonionic surfactant is a polyethylene glycol type one having an HLB of 10 to 14.
11. A pharmaceutical composition for rectal 2-0 administration according to Claim 1 or 3, wherein the anionic surfactant is an alkyl sulfate or a di-alkyl sulfosuccinate.
12. A pharmaceutical composition for rectal administration according to Claim 1 or 4, wherein the salt of bile acid is sodium tauroglycolate, sodium glycolate or sodium taurocholate.
13. A pharmaceutical composition for rectal administration according to Claim 1, wherein the amount - 20 4-8602 of the oily base is 1 to 20 times the weight of the cephalosporanic acid or its salt and the total amount of the nonionic surfactant, the anionic surfactant and the salt of bile acid is 1 to 20? by weight based on the 5 weight of the oily base.
14. A pharmaceutical composition for rectal administration according to Claim 13, wherein the amount of the oily base is 2 to 18 times the weight of the cephalosporanic acid or its salt and the total amount of 10 the nonionic surfactant, the anionic surfactant and the salt of bile acid is 5 to 10? by weight of the weight of the oily base.
15. A pharmaceutical composition for rectal administration according to Claim 1, 2, 3 or 4, wherein 15 the salt of cephalosporanic acid is an alkali metal salt, an alkaline earth metal salt, an ammonium salt, or a salt with an organic base.
16. A pharmaceutical composition for rectal administration according to Claim 1, 2, 3 or 4, wherein J.O the salt of cephalosporanic acid is a sodium, potassium, calcium, magnesium, ammonium, procain, dibenzylamine, N-benzyi-g-phenethylamine, 1-ephenamine, arginine or trishydroxymethylamine salt.
17. A pharmaceutical composition according to claim 1 and JL-5 substantially as hereinbefore set forth. Λ8602
18. A pharmaceutical composition substantially as hereinbefore set forth with reference to, and as illustrated in, the foregoing examples of the invention.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9000178A JPS5517342A (en) | 1978-07-25 | 1978-07-25 | Cephalosporin composition for rectal administaration |
Publications (2)
Publication Number | Publication Date |
---|---|
IE791411L IE791411L (en) | 1980-01-25 |
IE48602B1 true IE48602B1 (en) | 1985-03-20 |
Family
ID=13986352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE1411/79A IE48602B1 (en) | 1978-07-25 | 1979-08-08 | Pharmaceutical composition for rectal administration of 7-(d(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazinylcarboxamide)-p-hydroxyphenyl acetamido)-3-(5-(1-methyl-1,2,3,4-tetrazolyl)thiomethyl)-delta3-cephem-4-carboxylic acid or salts |
Country Status (27)
Country | Link |
---|---|
JP (1) | JPS5517342A (en) |
AU (1) | AU529031B2 (en) |
BE (1) | BE877831A (en) |
CA (1) | CA1123738A (en) |
CH (1) | CH641351A5 (en) |
CS (1) | CS268651B2 (en) |
DE (1) | DE2929840A1 (en) |
DK (1) | DK159136C (en) |
EG (1) | EG15790A (en) |
ES (1) | ES482818A1 (en) |
FI (1) | FI792303A (en) |
FR (1) | FR2433945A1 (en) |
GB (1) | GB2028655B (en) |
GR (1) | GR69652B (en) |
HU (1) | HU180965B (en) |
IE (1) | IE48602B1 (en) |
IL (1) | IL57846A (en) |
IN (1) | IN151264B (en) |
IT (1) | IT1118900B (en) |
LU (1) | LU81546A1 (en) |
NL (1) | NL7905708A (en) |
NO (1) | NO792443L (en) |
NZ (1) | NZ191053A (en) |
PH (1) | PH16496A (en) |
PT (1) | PT69969A (en) |
SE (1) | SE7906340L (en) |
ZA (1) | ZA793734B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4760059A (en) * | 1985-08-05 | 1988-07-26 | Hoffmann-La Roche Inc. | Rectal dosage form |
AT392906B (en) * | 1987-10-08 | 1991-07-10 | Hoffmann La Roche | Pharmaceutical products for oral administration |
US5190748A (en) * | 1988-11-22 | 1993-03-02 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
KR100739830B1 (en) * | 2001-03-23 | 2007-07-13 | 주식회사 하원제약 | Process for preparing Cephalosporin derivative |
US8075910B2 (en) | 2004-05-20 | 2011-12-13 | Pbm Pharmaceuticals, Inc. | Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions |
CN113637026A (en) * | 2020-05-11 | 2021-11-12 | 承德医学院 | Cefoperazone magnesium compound, and preparation method and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4950119A (en) * | 1972-09-21 | 1974-05-15 | ||
JPS5538925B2 (en) * | 1973-11-08 | 1980-10-07 | ||
GB1508071A (en) * | 1976-01-19 | 1978-04-19 | Toyama Chemical Co Ltd | Cephalosporins and process for producing the same |
JPS5244222A (en) * | 1975-09-30 | 1977-04-07 | Yamanouchi Pharmaceut Co Ltd | Method of making insulin preparations for rectal application |
JPS5822006B2 (en) * | 1975-12-12 | 1983-05-06 | 萬有製薬株式会社 | How to use this product |
JPS6055486B2 (en) * | 1976-02-28 | 1985-12-05 | 富山化学工業株式会社 | Composition for rectal administration of a compound having a β-lactam ring |
JPS52156918A (en) * | 1976-06-21 | 1977-12-27 | Sumitomo Chem Co Ltd | Preparation of penicillin pharmaceuticals for rectal infusion |
JPS5619847A (en) * | 1979-07-25 | 1981-02-24 | Hitachi Ltd | Manufacturing process for discharge lamp |
-
1978
- 1978-07-25 JP JP9000178A patent/JPS5517342A/en active Pending
-
1979
- 1979-07-16 GB GB7924710A patent/GB2028655B/en not_active Expired
- 1979-07-18 CA CA332,022A patent/CA1123738A/en not_active Expired
- 1979-07-18 NZ NZ191053A patent/NZ191053A/en unknown
- 1979-07-20 IN IN747/CAL/79A patent/IN151264B/en unknown
- 1979-07-20 IL IL57846A patent/IL57846A/en unknown
- 1979-07-20 ZA ZA00793734A patent/ZA793734B/en unknown
- 1979-07-21 EG EG439/79A patent/EG15790A/en active
- 1979-07-23 FR FR7918926A patent/FR2433945A1/en active Granted
- 1979-07-23 DE DE19792929840 patent/DE2929840A1/en active Granted
- 1979-07-23 GR GR59674A patent/GR69652B/el unknown
- 1979-07-23 HU HU79TO1112A patent/HU180965B/en unknown
- 1979-07-23 CH CH680379A patent/CH641351A5/en not_active IP Right Cessation
- 1979-07-23 DK DK310079A patent/DK159136C/en not_active IP Right Cessation
- 1979-07-23 FI FI792303A patent/FI792303A/en not_active Application Discontinuation
- 1979-07-24 NL NL7905708A patent/NL7905708A/en active Search and Examination
- 1979-07-24 PH PH22810A patent/PH16496A/en unknown
- 1979-07-24 ES ES482818A patent/ES482818A1/en not_active Expired
- 1979-07-24 SE SE7906340A patent/SE7906340L/en not_active Application Discontinuation
- 1979-07-24 LU LU81546A patent/LU81546A1/en unknown
- 1979-07-24 NO NO792443A patent/NO792443L/en unknown
- 1979-07-24 IT IT49844/79A patent/IT1118900B/en active
- 1979-07-24 CS CS795161A patent/CS268651B2/en unknown
- 1979-07-24 PT PT69969A patent/PT69969A/en unknown
- 1979-07-24 AU AU49191/79A patent/AU529031B2/en not_active Expired
- 1979-07-27 BE BE0/196403A patent/BE877831A/en not_active IP Right Cessation
- 1979-08-08 IE IE1411/79A patent/IE48602B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NZ191053A (en) | 1982-02-23 |
CS516179A2 (en) | 1989-09-12 |
AU529031B2 (en) | 1983-05-26 |
DE2929840C2 (en) | 1989-01-12 |
HU180965B (en) | 1983-05-30 |
SE7906340L (en) | 1980-01-27 |
NO792443L (en) | 1980-01-28 |
DK310079A (en) | 1980-01-26 |
PT69969A (en) | 1979-08-01 |
AU4919179A (en) | 1980-01-31 |
DE2929840A1 (en) | 1980-02-14 |
IN151264B (en) | 1983-03-19 |
CS268651B2 (en) | 1990-04-11 |
NL7905708A (en) | 1980-01-29 |
ZA793734B (en) | 1980-07-30 |
IT1118900B (en) | 1986-03-03 |
GR69652B (en) | 1982-07-07 |
GB2028655A (en) | 1980-03-12 |
IT7949844A0 (en) | 1979-07-24 |
EG15790A (en) | 1986-09-30 |
FR2433945A1 (en) | 1980-03-21 |
CH641351A5 (en) | 1984-02-29 |
BE877831A (en) | 1980-01-23 |
FI792303A (en) | 1980-01-26 |
DK159136C (en) | 1991-03-11 |
CA1123738A (en) | 1982-05-18 |
ES482818A1 (en) | 1980-09-01 |
JPS5517342A (en) | 1980-02-06 |
IE791411L (en) | 1980-01-25 |
IL57846A0 (en) | 1979-11-30 |
DK159136B (en) | 1990-09-10 |
FR2433945B1 (en) | 1984-12-14 |
GB2028655B (en) | 1982-12-22 |
PH16496A (en) | 1983-10-28 |
LU81546A1 (en) | 1980-01-24 |
IL57846A (en) | 1983-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5190748A (en) | Absorption enhancement of antibiotics | |
GB2051574A (en) | Adjuvant for promoting absorption of pharmacologically active substances through the rectum | |
AU625276B2 (en) | Pharmaceutical compositions | |
US4923862A (en) | Topical preparation containing ofloxacin | |
IE48602B1 (en) | Pharmaceutical composition for rectal administration of 7-(d(-)-alpha-(4-ethyl-2,3-dioxo-1-piperazinylcarboxamide)-p-hydroxyphenyl acetamido)-3-(5-(1-methyl-1,2,3,4-tetrazolyl)thiomethyl)-delta3-cephem-4-carboxylic acid or salts | |
US4596828A (en) | [(2-hydroxy-5-alkoxyphenyl)methylthio]phenylmethanol and derivatives thereof useful as anti-inflammatory agents | |
US3097135A (en) | Erythromycin suspensions and method of stabilizing the same | |
KR820002224B1 (en) | Process for preparing pharmceutical composition for rectal administration of cephalospirin | |
JPH0720865B2 (en) | Antibacterial agent | |
JPS6055486B2 (en) | Composition for rectal administration of a compound having a β-lactam ring | |
JPH0463047B2 (en) | ||
CA1157377A (en) | Pharmaceutical preparations for rectal administration, and the production and suppository base thereof | |
JPH03106827A (en) | Pharmaceutical composition | |
EP0250528A1 (en) | Oxazole derivatives and their use as anti-hyperglycaemic | |
JPH0455167B2 (en) | ||
EP0211434A2 (en) | Rectal dosage forms for ceftriaxone | |
JPS6230713A (en) | Antimicrobial solid composition for oral administration | |
JPS60169431A (en) | Stable antibacterial agent containing compound having beta-lactam ring and its preparation | |
CA2079328C (en) | Veterinary formulation of amoxycillin and clavulanic acid, and derivatives thereof | |
JPS60188320A (en) | Cephalosporin composition | |
CN113679725A (en) | Cephalosporin compound and application thereof in preparation of drugs for treating diabetes and complications | |
CN101153045B (en) | Novel cephalosporin compounds | |
JPH06305969A (en) | Suppository | |
JPS6263522A (en) | Drug preparation for rectal administration | |
JPS59212427A (en) | Composition for rectum administration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK9A | Patent expired |